Zevra Therapeutics Earnings Call Signals Profitable Turn

Zevra Therapeutics, Inc. ((ZVRA)) has held its Q4 earnings call. Read on for the main highlights of the call.

Zevra Therapeutics struck an upbeat tone on its latest earnings call, emphasizing that strong MIPLYFFA sales, a sharp swing to profitability, and a solid cash position more than offset ongoing challenges in an ultra‑rare market. Management acknowledged quarterly volatility, rising SG&A, and clinical delays but framed these as manageable against clear commercial traction and regulatory progress.

Robust Revenue Growth Led by MIPLYFFA

Zevra reported 2025 net revenue of $106.5 million, with $34.1 million generated in the fourth quarter, underscoring solid top‑line momentum. MIPLYFFA drove the story, contributing $87.4 million, or 82% of full‑year revenue, and $26.4 million, or 77% of Q4 revenue, confirming its role as the company’s primary growth engine.

Profitability Swings Sharply Into the Black

The company delivered a dramatic profitability turnaround, posting 2025 net income of $83.2 million, or $1.40 basic per share, versus a $105.5 million loss in 2024. Fourth‑quarter 2025 net income was $12.2 million, reversing a Q4 2024 net loss of $35.7 million and highlighting improved operating efficiency and revenue scale.

Commercial Momentum and U.S. Patient Uptake

Commercial metrics reinforced the revenue performance, with 52 prescription enrollment forms in 2025, including 24 in the fourth quarter, and 161 total MIPLYFFA enrollments since launch. Management believes it has already captured about 40% to 50% of currently diagnosed U.S. patients, a penetration level that supports confidence in further adoption as diagnosis and awareness improve.

Expanded Access Drives International Reach

The global expanded access program continued to build Zevra’s international footprint, ending 2025 with 113 enrolled patients. New distribution agreements extended shipments beyond Europe and generated $5.6 million of net EAP reimbursements in the fourth quarter, or $13 million for the year, providing both revenue and real‑world usage data.

Advancing Regulatory Pathway in Europe

On the regulatory front, Zevra has submitted a Marketing Authorization Application for MIPLYFFA to the European Medicines Agency, marking a key step toward EU approval. The company received the standard 120‑day list of questions at year‑end and said it is prepared to respond within the 90‑day clock‑stop, keeping the review process moving.

Strong U.S. Market Access Underpins Growth

Market access in the United States is another pillar of the story, with approximately 68% of U.S. covered lives secured after the first full year on market. Management cited strong reimbursement rates for remaining patients, crediting targeted market access work and patient services for smoothing the path to therapy.

Balance Sheet Supports Expansion Plans

Zevra closed 2025 with $238.9 million in cash, cash equivalents, and investments against roughly $61.9 million of total debt, leaving it well capitalized. The company said this runway is sufficient to fund commercial expansion and clinical programs, including ongoing work around MIPLYFFA and the celiprolol program.

Cost Discipline and R&D Pullback

Operating expenses for 2025 fell to $90.4 million, a year‑over‑year decrease of $6.6 million that signals tighter cost control. Research and development spending dropped to $12.7 million, down $29.4 million, or nearly 70%, mainly from lower personnel and third‑party costs as some programs wound down or shifted phase.

Clinical and Real‑World Evidence Bolster MIPLYFFA

Management spotlighted data supporting MIPLYFFA’s clinical profile, including rapid improvements within 12 weeks and halted disease progression at 12 months. Longer‑term follow‑up above five years, along with presentations and EAP analyses, showed durable efficacy, sustained benefit, and strong adherence in real‑world use.

Revenue Volatility in an Ultra‑Rare Market

Executives cautioned that quarter‑to‑quarter variability will remain a feature of the business given the ultra‑rare patient pool, where a single patient can meaningfully shift results. This dynamic can create noise in short‑term revenue and enrollment cadence, although management argued the underlying trajectory remains positive.

Higher SG&A Weighs on Operating Leverage

Selling, general, and administrative expenses climbed as Zevra invested behind the launch, with Q4 SG&A reaching $20.4 million, up about 27% versus the prior year. For 2025 as a whole, SG&A rose $22.7 million to $77.6 million, temporarily limiting operating leverage even as overall operating expenses declined.

Slow Progress in Celiprolol Phase III Trial

The Phase III DISCOVER study of celiprolol is progressing more slowly than hoped, with 52 of 150 patients enrolled at year‑end and just eight added in the fourth quarter. Only one of the 28 required events has occurred for the interim analysis, pushing out timelines and leaving this potential growth driver further on the horizon.

Persistency Metrics Still Developing

While refill patterns for MIPLYFFA are described as encouraging, management said it is too early to report robust 12‑month on‑treatment rates. Long‑term commercial persistency data remain immature, and investors will need to watch future updates for a clearer picture of lifetime revenue per patient.

Regulatory and Exclusivity Risks

Zevra acknowledged that the EMA review process, including clock‑stops around its questions, can extend the path to a final decision in Europe. The company is also pursuing patent term extension in the United States, but outcomes are uncertain and could influence how long MIPLYFFA maintains protection beyond existing orphan exclusivity.

Gross‑to‑Net and Pricing Variability

Management flagged some uncertainty in gross‑to‑net dynamics, pointing to a one‑off impact in the third quarter tied to policy changes and evolving reimbursement. They declined to offer precise forward guidance on realized pricing, signaling that discounts, rebates, and payer behavior could add variability to reported revenue.

Competitive Landscape and Diagnosis Challenges

Potential competitors, including therapies targeting specific subpopulations, could eventually pressure MIPLYFFA’s share, even as Zevra sees it as a foundational treatment. The company also noted that diagnosis timelines vary widely in this ultra‑rare disease, requiring continued investment to identify eligible patients and sustain growth.

Outlook and Forward‑Looking Guidance

For 2026, management expects growth to be driven by continued U.S. commercial execution for MIPLYFFA and additional leverage from expanded access and coverage, albeit with ongoing quarterly swings. The company plans to respond to EMA questions within the allowed window, pursue a U.S. patent‑term extension, restart and advance the DISCOVER trial ahead of further regulator discussions, and prioritize capital toward high‑impact initiatives.

Zevra’s latest earnings call painted the picture of a rare‑disease specialist that has crossed a key inflection point, using one breakout product to power revenue growth and profitability. While investors must factor in clinical delays, cost pressures, and inherent volatility, the combination of strong cash, expanding access, and regulatory momentum gives the company a solid footing for its next phase of growth.